CMA Recommendations on Canada’s First National Adaptation Strategy: Addressing the health impacts of climate change
https://policybase.cma.ca/link/policy14484

POLICY TYPE  Parliamentary submission
DATE  2022-06-23
TOPICS  Population health, health equity, public health
Health systems, system funding and performance

Documents
CMA Recommendations on Vaccine Equity and Intellectual Property
https://policybase.cma.ca/link/policy14476

POLICY TYPE  Parliamentary submission
DATE  2022-05-13

TOPICS  Ethics and medical professionalism
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Appearance before the Standing Committee on Indigenous and Northern Affairs (INAN): Administration and accessibility of Indigenous Peoples to the Non-Insured Benefits Program

https://policybase.cma.ca/link/policy14474

POLICY TYPE  Parliamentary submission
DATE  2022-05-03
TOPICS  Population health, health equity, public health
Ethics and medical professionalism

Documents
Canadian Medical Association input in advance of the World Health Assembly Special Session
https://policybase.cma.ca/link/policy14461

POLICY TYPE
Parliamentary submission

DATE
2021-11-17

TOPICS
Population health, health equity, public health
Ethics and medical professionalism

Documents
New Criminal Code offence to protect health workers from threats and violence, including online
https://policybase.cma.ca/link/policy14463

POLICY TYPE
Parliamentary submission

DATE
2021-11-16

TOPICS
Population health, health equity, public health
Ethics and medical professionalism

Documents
Disclosure of COVID-19 Vaccination Status by Physicians

POLICY TYPE
Policy document

DATE
2021-10-22

TOPICS
Physician practice, compensation, forms

Documents
COVID-19 Vaccine Global Intellectual Property Policy

**Policy document**

**Date**
2021-10-22

**Topics**
Physician practice, compensation, forms

**Documents**

---

COVID-19 Vaccine Global Intellectual Property Policy

Policy position recommendation

1. The CMA encourages governments of countries to participate in the global dialogue, led by the World Trade Organization, the World Health Organization, the World Intellectual Property Organization, and the United Nations, to facilitate the participation of developing countries in the production and distribution of COVID-19 vaccines.

2. The CMA encourages governments of countries to support a temporary, multilateral, patent waiving mechanism under the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) to facilitate access to COVID-19 vaccines.

3. The CMA encourages governments of countries to cooperate to support local production of COVID-19 vaccines in developing countries, recognizing that this requires a coordinated and collaborative approach among all stakeholders.

4. In support of these policy positions, the CMA recommends:
   - Advocating for and supporting a comprehensive global health strategy that prioritizes equitable access to COVID-19 vaccines, treatments, and tests.
   - Encouraging global health research and innovation to address the urgent needs of developing countries.
   - Supporting the strengthening of health systems in developing countries to ensure sustainable and equitable access to COVID-19 vaccines.
   - Promoting international cooperation and partnerships to address the global health crisis.

5. The CMA calls on all stakeholders, including governments, pharmaceutical companies, and civil society organizations, to work together to ensure that the benefits of COVID-19 vaccine development and delivery are equitably distributed.
The Lancet Countdown on Health and Climate Change – Policy brief for Canada, October 2021
https://policybase.cma.ca/link/policy14455

POLICY TYPE  
Policy endorsement

DATE  
2021-10-20

TOPICS  
Population health, health equity, public health

Documents
São Paulo Declaration on Planetary Health

https://policybase.cma.ca/link/policy14456

POLICY TYPE
Policy endorsement

DATE
2021-10-04

TOPICS
Population health, health equity, public health

Documents
Vaccine certificates
https://policybase.cma.ca/link/policy14448

Policy document

DATE 2021-08-21

TOPICS Population health, health equity, public health
Ethics and medical professionalism

Documents
Mandatory COVID-19 vaccination of health care workers

POLICY TYPE  Policy document
DATE       2021-08-21
TOPICS     Health human resources
Population health, health equity, public health

Documents

Mandatory COVID-19 vaccination of health care workers

Policy position statement:
1. All health care workers should be strongly encouraged to follow the COVID-19 vaccine recommendations. They should be informed about the benefits and risks of the vaccine, and the evidence supporting its efficacy. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.
2. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.
3. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.
4. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.
5. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.
6. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.
7. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.
8. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.
9. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.
10. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.

COVID-19 vaccination of health care workers

Policy position statement:
1. All health care workers should be strongly encouraged to follow the COVID-19 vaccine recommendations. They should be informed about the benefits and risks of the vaccine, and the evidence supporting its efficacy. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.
2. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.
3. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.
4. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.
5. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.
6. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.
7. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.
8. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.
9. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.
10. Health care workers should be provided with information about the vaccine's safety and efficacy, as well as the potential for adverse reactions.
Vaccine acceptance
https://policybase.cma.ca/link/policy14450

POLICY TYPE  Policy document
DATE          2021-08-21
TOPICS        Health care and patient safety
              Population health, health equity, public health

Documents

Vaccine acceptance

Facts and position statement
1. High levels of vaccine coverage are critical to the success of the pandemic. Public health programs need robust and effective strategies to ensure access and delivery. The use
   of digital technology is critical.
2. It is important to gain the trust of all communities to increase vaccine uptake. Vaccination
   clinics should be accessible, easy to understand, and widely advertised. The use of digital
   technology is crucial to this effort.
3. The CMA calls on all levels of government to ensure that vaccine distribution is transparent and
   accessible to all communities. The use of digital technology is essential to this effort.
4. The CMA supports the development of comprehensive immunization programs that
   address the needs of all communities.

Implications
1. The implications for global health and the prevention of vaccine preventable diseases
   are significant.
2. The implications for individual health and the prevention of vaccine preventable diseases
   are significant.

CMA Policybase - Canadian Medical Association
Global vaccine equity

https://policybase.cma.ca/link/policy14451

POLICY TYPE  Policy document
DATE  2021-08-21
TOPICS  Ethics and medical professionalism
Population health, health equity, public health

Global vaccine equity

Policy position recommendation:

1. Lower priority for vaccine acquisition to vaccine-eligible adults in low and middle-income countries, especially in sub-Saharan Africa, and divert resources to manufacture and ensure access to other essential medicines for malaria, HIV/AIDS, and tuberculosis.

2. Support for vaccine distribution through the COVAX mechanism.

3. Support for the development of vaccines that are more suitable for the global population.

4. Support for the development of vaccines that are more effective in low-income countries.

5. Support for the development of vaccines that are more affordable in low-income countries.

6. Support for the development of vaccines that are more accessible in low-income countries.

7. Support for the development of vaccines that are more sustainable in low-income countries.

8. Support for the development of vaccines that are more effective in low-income countries.

9. Support for the development of vaccines that are more affordable in low-income countries.

10. Support for the development of vaccines that are more accessible in low-income countries.

11. Support for the development of vaccines that are more sustainable in low-income countries.

12. Support for the development of vaccines that are more effective in low-income countries.

13. Support for the development of vaccines that are more affordable in low-income countries.

14. Support for the development of vaccines that are more accessible in low-income countries.

15. Support for the development of vaccines that are more sustainable in low-income countries.

16. Support for the development of vaccines that are more effective in low-income countries.

17. Support for the development of vaccines that are more affordable in low-income countries.

18. Support for the development of vaccines that are more accessible in low-income countries.

19. Support for the development of vaccines that are more sustainable in low-income countries.

20. Support for the development of vaccines that are more effective in low-income countries.

21. Support for the development of vaccines that are more affordable in low-income countries.

22. Support for the development of vaccines that are more accessible in low-income countries.

23. Support for the development of vaccines that are more sustainable in low-income countries.

24. Support for the development of vaccines that are more effective in low-income countries.

25. Support for the development of vaccines that are more affordable in low-income countries.

26. Support for the development of vaccines that are more accessible in low-income countries.

27. Support for the development of vaccines that are more sustainable in low-income countries.

28. Support for the development of vaccines that are more effective in low-income countries.

29. Support for the development of vaccines that are more affordable in low-income countries.

30. Support for the development of vaccines that are more accessible in low-income countries.

31. Support for the development of vaccines that are more sustainable in low-income countries.

32. Support for the development of vaccines that are more effective in low-income countries.

33. Support for the development of vaccines that are more affordable in low-income countries.

34. Support for the development of vaccines that are more accessible in low-income countries.

35. Support for the development of vaccines that are more sustainable in low-income countries.

36. Support for the development of vaccines that are more effective in low-income countries.

37. Support for the development of vaccines that are more affordable in low-income countries.

38. Support for the development of vaccines that are more accessible in low-income countries.

39. Support for the development of vaccines that are more sustainable in low-income countries.

40. Support for the development of vaccines that are more effective in low-income countries.

41. Support for the development of vaccines that are more affordable in low-income countries.

42. Support for the development of vaccines that are more accessible in low-income countries.

43. Support for the development of vaccines that are more sustainable in low-income countries.

44. Support for the development of vaccines that are more effective in low-income countries.

45. Support for the development of vaccines that are more affordable in low-income countries.

46. Support for the development of vaccines that are more accessible in low-income countries.

47. Support for the development of vaccines that are more sustainable in low-income countries.

48. Support for the development of vaccines that are more effective in low-income countries.

49. Support for the development of vaccines that are more affordable in low-income countries.

50. Support for the development of vaccines that are more accessible in low-income countries.

51. Support for the development of vaccines that are more sustainable in low-income countries.

52. Support for the development of vaccines that are more effective in low-income countries.

53. Support for the development of vaccines that are more affordable in low-income countries.

54. Support for the development of vaccines that are more accessible in low-income countries.

55. Support for the development of vaccines that are more sustainable in low-income countries.

56. Support for the development of vaccines that are more effective in low-income countries.

57. Support for the development of vaccines that are more affordable in low-income countries.

58. Support for the development of vaccines that are more accessible in low-income countries.

59. Support for the development of vaccines that are more sustainable in low-income countries.

60. Support for the development of vaccines that are more effective in low-income countries.
Return to school during COVID-19

https://policybase.cma.ca/link/policy14452

POLICY TYPE  Policy document
DATE  2021-08-21
TOPICS  Health care and patient safety
         Population health, health equity, public health

Documents
Interchangeability of vaccines (vaccine mixing)

https://policybase.cma.ca/link/policy14453

Policy document

DATE 2021-08-21

TOPICS Health care and patient safety
Population health, health equity, public health

Documents
Firearms Control (Update 2021)
https://policybase.cma.ca/link/policy14401

POLICY TYPE
Policy document

DATE
2021-07-15

REPLACES
Firearms control (Update 2001)

TOPICS
Population health, health equity, public health
Health care and patient safety

Documents
Policy Brief: CSAM-SMCA in Support of the Decriminalization of Drug Use and Possession for Personal Use
https://policybase.cma.ca/link/policy14443

POLICY TYPE
Policy endorsement

DATE
2021-06-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
The Future of Care for Canada’s Older Adults
https://policybase.cma.ca/link/policy14441

POLICY TYPE  Parliamentary submission
DATE  2021-06-23
TOPICS  Population health, health equity, public health

Documents
Appearance before the House of Commons Standing Committee on Finance
Bill C-30: The Budget Implementation Act, 2021
https://policybase.cma.ca/link/policyl4437

POLICY TYPE: Parliamentary submission
DATE: 2021-05-20
TOPICS: Population health, health equity, public health

Documents

Appearance before the House of Commons Standing Committee on Finance
Bill C-30: The Budget Implementation Act, 2021

Dr. E. Ann Galles
President of the Canadian Medical Association
May 20, 2021

Canadian Medical Association
Enhancing equitable access to virtual care in Canada: Principle-based recommendations for equity
https://policybase.cma.ca/link/policy14447

POLICY TYPE  Policy endorsement
DATE  2021-04-30
TOPICS  Population health, health equity, public health
Health information and e-health

Documents